Developing MRI Technologies for Atrial Fibrillation

NCT07083115 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-03-23

No results posted yet for this study

Summary

To measure image quality of damaged areas of the heart in patients with Atrial fibrillation using the contrast Gadopiclenol vs conventional Gadolinium-based contrast agents(GBCA)

Conditions

  • Atrial Fibrillation (AF)

Sponsors & Collaborators

  • Guerbet

    collaborator INDUSTRY
  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Christopher Nguyen, PhD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2027-09-30
Completion
2028-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07083115 on ClinicalTrials.gov